Abiopharma

🔍 LUSTIG MATTHEW J (Director)

Company: Ventas, Inc. (VTR)

Report Date: 2026-04-16

Detailed Transactions and Holdings:

• Acquired 229 shares of Common Stock at $85.51 per share (Direct)
  Date: 2026-04-16 | Code: A | equity_swap_involved: 0 | shares_owned_after: 92,891.97 | transaction_form_type: 4 | Footnotes: F1, F2
• Acquired 67 shares of Common Stock at $85.51 per share (Direct)
  Date: 2026-04-16 | Code: A | equity_swap_involved: 0 | shares_owned_after: 92,958.71 | transaction_form_type: 4 | Footnotes: F3, F2

Footnotes:

• F1: Common stock in the form of units granted under the Ventas, Inc. Non-Employee Directors' Cash Compensation Deferral Plan (the "Plan") as a result of dividend equivalents credited with respect to the dividend on Issuer's common stock paid on April 16, 2026. Such units are payable solely in common stock and subject to the terms and conditions of the Reporting Person's deferral election and the Plan.
• F2: Represents the closing price per share of Issuer's common stock as of the grant date.
• F3: Common stock in the form of units granted under the Ventas, Inc. Non-Employee Directors' Equity Award Deferral Program (the "Program") adopted pursuant to the Ventas, Inc. 2022 Incentive Plan as a result of dividend equivalents credited with respect to the dividend on Issuer's common stock paid on April 16, 2026. Such units are payable solely in common stock and subject to the terms and conditions of the Reporting Person's deferral election and the Program.